Canakinumab in Patients With Active Hyper-IgD Syndrome
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This pilot study is designed to evaluate the efficacy, the safety, and the pharmacokinetics
(PK) / pharmacodynamics (PD) of canakinumab treatment in patients with HIDS.